Linagliptin, which is approved in the US, the European Union, Japan and other countries, including India, is an original research product of Boehringer.
Lilly India managing director Melt van der Spuy was quoted by pharmabiz as saying that the launch of linagliptin marks an important milestone for the alliance.
"The alliance will continue to focus on bringing to India innovative products and services to address the unmet patients needs amidst the growing Indian diabetes epidemic," Melt van der Spuy added.
The Boehringer Ingelheim-Lilly alliance in India now offers oral anti-diabetics in addition to contemporary injectable insulins.